Key result
Successful PTCA in the pre-drug-eluting stent era carries an 11% overall clinical restenosis rate.
Why the study?
To document interventional cardiology practice, clinical restenosis rates, and associated risk factors in daily practice to provide perspective for drug-eluting stents.
Population
3177 consecutive patients undergoing successful PTCA in the Netherlands
Design
Prospective cohort study
Follow-up
9.6 months, IQR 3.9
Authors
Loading...
Clinical restenosis persists after PTCA in unselected patients; leaves open whether drug-eluting stents will improve routine outcomes.
Cohort (n=3,177)
In the pre-drug-eluting stent era, clinical restenosis after successful PTCA occurred in approximately 11-12% of patients at 1 year, highlighting a baseline event rate to compare against newer devices.
Willem R.P. Agema (2004) conducted a cohort in Stable and unstable angina requiring PTCA (n=3,177). Percutaneous transluminal coronary angioplasty (PTCA) was evaluated on Clinical restenosis (cardiac death, myocardial infarction and revascularisation of the target vessel). In patients undergoing successful PTCA in the pre-drug-eluting stent era, clinical restenosis occurred in 11.0% overall, with rates of 10.2% and 12.0% at 9 and 12 months, respectively.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: